Pfizer narrows review for Zyrtec

Published on .

Pfizer is believed to have narrowed the list of agencies in contention for its estimated $75 million Zyrtec anti-allergy drug account. Deutsch; Kirshenbaum, Bond & Partners; Merkley Newman Harty; Ogilvy & Mather Worldwide; and McCann-Erickson Worldwide are all believed to be finalists. A Pfizer spokeswoman declined comment.

Copyright June 1999, Crain Communications Inc.

In this article:
Most Popular